SVIP Activators
Small VCP/p97-interacting protein (SVIP) is a protein that interacts with valosin-containing protein (VCP), also known as p97, which is a member of the AAA+ (ATPases Associated with various cellular Activities) family of ATPases. VCP/p97 is involved in a multitude of cellular processes, including protein degradation, membrane fusion, and the stress response, typically by remodeling or extracting proteins from complexes or membranes.SVIP, as an interacting partner, modulates the function of VCP/p97. It is characterized as a small protein that can bind to VCP/p97 and influence its activity. By interacting with VCP/p97, SVIP can affect various cellular pathways involving VCP/p97, including those related to the endoplasmic reticulum (ER) associated degradation (ERAD) pathway, where misfolded proteins are targeted for degradation to maintain cellular homeostasis.
The ERAD pathway is critical for the quality control of proteins within the ER, and VCP/p97 has a central role in this process by extracting misfolded proteins from the ER and delivering them to the proteasome for degradation. SVIP's interaction with VCP/p97 suggests that SVIP may help regulate this process, possibly by serving as a cofactor that modulates the specificity or efficiency of VCP/p97-mediated protein degradation.Additionally, alterations in SVIP expression levels have been implicated in various pathophysiological conditions. For example, overexpression of SVIP has been associated with the accumulation of misfolded proteins within the ER, leading to ER stress and potentially contributing to diseases such as neurodegeneration.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
NMS-873 | 1418013-75-8 | sc-478803 | 5 mg | $300.00 | ||
NMS-873 is an allosteric inhibitor of VCP/p97, potentially affecting SVIP activity by altering the function of VCP/p97 in protein degradation pathways. | ||||||
PFI-1 | 1403764-72-6 | sc-478504 | 5 mg | $98.00 | ||
ML241 is another VCP/p97 inhibitor that could indirectly modulate SVIP activity through its impact on VCP/p97-mediated protein processing. | ||||||
ONX 0914 | 960374-59-8 | sc-477437 | 5 mg | $245.00 | ||
ONX 0914 is an immunoproteasome inhibitor that could indirectly affect SVIP by altering proteasome-mediated protein degradation processes. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib, a proteasome inhibitor, might influence SVIP activity indirectly through its broad impact on the ubiquitin-proteasome system. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib is another proteasome inhibitor whose modulation of proteasome activity could have secondary effects on SVIP function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor and could indirectly affect SVIP activity through its influence on proteasome-mediated protein degradation. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib, a proteasome inhibitor, may impact SVIP activity indirectly by affecting overall protein degradation dynamics. | ||||||